vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and STAG Industrial, Inc. (STAG). Click either name above to swap in a different company.
STAG Industrial, Inc. is the larger business by last-quarter revenue ($224.2M vs $191.2M, roughly 1.2× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 9.1%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 8.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Stag Arms is a firearms manufacturer founded in May 2003 and located in Cheyenne, Wyoming. Stag Arms is a manufacturer of the AR-15 type rifle, marketed as Stag-15 rifles. Stag advertises that all their weapons and accessories are made in the United States. They are best known for their left-handed AR-15 rifles, which use a mirror imaged upper receiver and have the ejection port reversed for left-handed shooters and the safety selector control on the right side of the lower receiver.
AXSM vs STAG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $224.2M |
| Net Profit | — | $62.0M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 27.6% |
| Revenue YoY | 57.4% | 9.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $224.2M | ||
| Q4 25 | $196.0M | $220.9M | ||
| Q3 25 | $171.0M | $211.1M | ||
| Q2 25 | $150.0M | $207.6M | ||
| Q1 25 | $121.5M | $205.6M | ||
| Q4 24 | $118.8M | $199.3M | ||
| Q3 24 | $104.8M | $190.7M | ||
| Q2 24 | $87.2M | $189.8M |
| Q1 26 | — | $62.0M | ||
| Q4 25 | $-28.6M | $83.5M | ||
| Q3 25 | $-47.2M | $48.6M | ||
| Q2 25 | $-48.0M | $50.0M | ||
| Q1 25 | $-59.4M | $91.4M | ||
| Q4 24 | $-74.9M | $51.0M | ||
| Q3 24 | $-64.6M | $41.9M | ||
| Q2 24 | $-79.3M | $59.8M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — |
| Q1 26 | — | 27.6% | ||
| Q4 25 | -14.6% | 37.8% | ||
| Q3 25 | -27.6% | 23.0% | ||
| Q2 25 | -32.0% | 24.1% | ||
| Q1 25 | -48.9% | 44.5% | ||
| Q4 24 | -63.1% | 25.6% | ||
| Q3 24 | -61.7% | 21.9% | ||
| Q2 24 | -91.0% | 31.5% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $8.9M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $3.6B |
| Total Assets | $713.6M | $7.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $8.9M | ||
| Q4 25 | $322.9M | $14.9M | ||
| Q3 25 | $325.3M | $17.3M | ||
| Q2 25 | $303.0M | $15.4M | ||
| Q1 25 | $300.9M | $9.3M | ||
| Q4 24 | $315.4M | $36.3M | ||
| Q3 24 | $327.3M | $70.0M | ||
| Q2 24 | $315.7M | $33.3M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.8B |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $88.3M | $3.6B | ||
| Q3 25 | $73.7M | $3.4B | ||
| Q2 25 | $73.1M | $3.4B | ||
| Q1 25 | $53.2M | $3.5B | ||
| Q4 24 | $57.0M | $3.5B | ||
| Q3 24 | $92.9M | $3.3B | ||
| Q2 24 | $102.9M | $3.3B |
| Q1 26 | $713.6M | $7.2B | ||
| Q4 25 | $689.8M | $7.2B | ||
| Q3 25 | $669.3M | $6.9B | ||
| Q2 25 | $639.8M | $6.8B | ||
| Q1 25 | $596.7M | $6.8B | ||
| Q4 24 | $568.5M | $6.8B | ||
| Q3 24 | $561.5M | $6.6B | ||
| Q2 24 | $548.2M | $6.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.91× | ||
| Q3 25 | — | 0.91× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
STAG
Segment breakdown not available.
